A PHASE 2 STUDY OF MUTANT-SELECTIVE PI3K INHIBITOR, RLY-2608, IN ADULTS AND CHILDREN WITH PIK3CA RELATED OVERGROWTH SPECTRUM AND MALFORMATIONS DRIVEN BY PIK3CA MUTATION

Registry ID

RLY-2608-201

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

RELAY THERAPEUTICS, INC.

Last update

2025-08-18

Conditions

• PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)

Related clinical trials

• EPIK-P2: A PHASE II DOUBLE-BLIND STUDY WITH AN UPFRONT, 16-WEEK RANDOMIZED PLACEBO-CONTROLLED PERIOD, TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF ALPELISIB (BYL719) IN PEDIATRIC AND ADULT PATIENTS WITH PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)

View on source registry